Published :
Tables : 49
Figures : 44
Category : Healthcare
No. of Pages : 226
Report Code : HC-1275
Molecular Diagnostics Market is poised to value USD 31808 million by 2028 end at a CAGR of 5.4% during the forecast period 2022 to 2028. The reagents subjugated the global market with respect to revenue in 2018. Rising usage of reagents in testing molecular diagnostics, high demand for diagnostic tests provided over-the-counter and increasing adoption of such tests in nonmedical applications are some of the factors bolstering the global market growth. The central laboratories subjugated the market with respect to revenue share in 2018 due to high procedural volumes and a substantial prevalence of additional support with respect to infrastructure and manpower. The segment that is predicted to showcase rapid growth over the forecast period is the point of care segment. Rising demands for patient care at bedside due to prospering home healthcare along with rising penetration of localised establishments of healthcare is one of the primary factors responsible for its rapid growth. Furthermore, OTC products or self-tests are gaining popularity with consistent improvements in healthcare facilities and levels of patient awareness is anticipated to assist in the segment growth. The PCR segment subjugated the global market in 2018. PCR is a commonly used molecular diagnostics technology. Advancements and increased usage in PCR methods like multiplex PCR are some of the key factors responsible for the overall global market growth. Sequencing is predicted to showcase substantial growth during the forecast time frame due to factors like rising portability and likely cos reduction of DNA sequencers coupled with the NGS methods, offering high output sequencing and analysis of gene data. Moreover, In Situ Hybridization is expected to showcase significant growth over the forecast period. An increase in the population affected by cancer and the necessity for early diagnosis of cancer are some of the key factors aiding in the expansion of the overall global market size. Increasing prevalence of cancer and the development of novel tests like companion diagnostics for diagnosing cancer are some of the important factors that are predicted to contribute to the high value of CAGR during the forecast period. North America led the market in terms of generating revenue in 2018 and it is predicted to show the same market trend throughout the forecast period. North America is the leader of the industry due to the provisions of an established infrastructure for diagnostics, advancements in technology and rising awareness of patients. Massive prevalence of patient population and numerous unsatisfied clinical needs are expected to steer the market in the Asia Pacific region. Increasing economic initiatives by the governments of India and China in order to enhance the healthcare infrastructure are factors that are predicted to spur market augmentation. Major players included in the Molecular Diagnostics Market: • F. Hoffmann-La Roche Ltd. • Hologic, Inc. • BioMérieux SA • Abbott Laboratories • Qiagen • Thermo Fisher Scientific Inc. • Siemens Healthineers AG • Danaher Corporation • Myriad Genetics Inc. • Illumina Inc. • Agilent Technologies Inc. • Becton, Dickinson and Company • DiaSorin S.p.A • Grifols S.A. • Quidel Corporation • Genetic Signatures • MDxHealth, Inc. • Exact Sciences Corporation • Biocartis NV • TBG Diagnostics Ltd. (Note: The list of the major players will be updated with the latest market scenario and trends) Molecular Diagnostics Market Segmentation: By Product • Reagents & kits • Instruments o Tabletop Instruments o Portable & PoC Instruments • Services & Software By Technology • Polymerase Chain Reaction (PCR) • Isothermal Nucleic Acid Amplification Technology (INAAT) • DNA Sequencing & Next-Generation Sequencing (NGS) • In Situ Hybridization (ISH) • DNA Microarrays • Other technologies By Application • Infectious Disease Diagnostics o COVID-19 o Hepatitis o HIV o CT/NG o HAI o HPV o Tuberculosis o Influenza o Other Infectious Diseases • Oncology Testing o Breast Cancer o Colorectal Cancer o Lung Cancer o Prostate Cancer o Other Cancers • Genetic Tests • Other Applications By End User • Diagnostic Laboratories • Hospitals and Clinics • Other End Users By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Molecular Diagnostics Market By Product, By Technology, By Application, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The reagents subjugated the global market with respect to revenue in 2018. Rising usage of reagents in testing molecular diagnostics, high demand for diagnostic tests provided over-the-counter and increasing adoption of such tests in nonmedical applications are some of the factors bolstering the global market growth. The central laboratories subjugated the market with respect to revenue share in 2018 due to high procedural volumes and a substantial prevalence of additional support with respect to infrastructure and manpower. The segment that is predicted to showcase rapid growth over the forecast period is the point of care segment. Rising demands for patient care at bedside due to prospering home healthcare along with rising penetration of localised establishments of healthcare is one of the primary factors responsible for its rapid growth. Furthermore, OTC products or self-tests are gaining popularity with consistent improvements in healthcare facilities and levels of patient awareness is anticipated to assist in the segment growth. The PCR segment subjugated the global market in 2018. PCR is a commonly used molecular diagnostics technology. Advancements and increased usage in PCR methods like multiplex PCR are some of the key factors responsible for the overall global market growth.
Sequencing is predicted to showcase substantial growth during the forecast time frame due to factors like rising portability and likely cos reduction of DNA sequencers coupled with the NGS methods, offering high output sequencing and analysis of gene data. Moreover, In Situ Hybridization is expected to showcase significant growth over the forecast period. An increase in the population affected by cancer and the necessity for early diagnosis of cancer are some of the key factors aiding in the expansion of the overall global market size. Increasing prevalence of cancer and the development of novel tests like companion diagnostics for diagnosing cancer are some of the important factors that are predicted to contribute to the high value of CAGR during the forecast period.
North America led the market in terms of generating revenue in 2018 and it is predicted to show the same market trend throughout the forecast period. North America is the leader of the industry due to the provisions of an established infrastructure for diagnostics, advancements in technology and rising awareness of patients.
Massive prevalence of patient population and numerous unsatisfied clinical needs are expected to steer the market in the Asia Pacific region. Increasing economic initiatives by the governments of India and China in order to enhance the healthcare infrastructure are factors that are predicted to spur market augmentation.
Major players included in the Molecular Diagnostics Market: • F. Hoffmann-La Roche Ltd. • Hologic, Inc. • BioMérieux SA • Abbott Laboratories • Qiagen • Thermo Fisher Scientific Inc. • Siemens Healthineers AG • Danaher Corporation • Myriad Genetics Inc. • Illumina Inc. • Agilent Technologies Inc. • Becton, Dickinson and Company • DiaSorin S.p.A • Grifols S.A. • Quidel Corporation • Genetic Signatures • MDxHealth, Inc. • Exact Sciences Corporation • Biocartis NV • TBG Diagnostics Ltd. (Note: The list of the major players will be updated with the latest market scenario and trends)
Molecular Diagnostics Market Segmentation: By Product • Reagents & kits • Instruments o Tabletop Instruments o Portable & PoC Instruments • Services & Software
By Technology • Polymerase Chain Reaction (PCR) • Isothermal Nucleic Acid Amplification Technology (INAAT) • DNA Sequencing & Next-Generation Sequencing (NGS) • In Situ Hybridization (ISH) • DNA Microarrays • Other technologies
By Application • Infectious Disease Diagnostics o COVID-19 o Hepatitis o HIV o CT/NG o HAI o HPV o Tuberculosis o Influenza o Other Infectious Diseases • Oncology Testing o Breast Cancer o Colorectal Cancer o Lung Cancer o Prostate Cancer o Other Cancers • Genetic Tests • Other Applications
By End User • Diagnostic Laboratories • Hospitals and Clinics • Other End Users
By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Molecular Diagnostics Market By Product, By Technology, By Application, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Product launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Molecular Diagnostics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Molecular Diagnostics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Molecular Diagnostics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Molecular Diagnostics Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Reagents & kits 7.2. Instruments 7.2.1. Tabletop Instruments 7.2.2. Portable & PoC Instruments 7.3. Services & Software 8. Molecular Diagnostics Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Polymerase Chain Reaction (PCR) 8.2. Isothermal Nucleic Acid Amplification Technology (INAAT) 8.3. DNA Sequencing & Next-Generation Sequencing (NGS) 8.4. In Situ Hybridization (ISH) 8.5. DNA Microarrays 8.6. Other technologies 9. Molecular Diagnostics Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Infectious Disease Diagnostics 9.1.1. COVID-19 9.1.2. Hepatitis 9.1.3. HIV 9.1.4. CT/NG 9.1.5. HAI 9.1.6. HPV 9.1.7. Tuberculosis 9.1.8. Influenza 9.1.9. Other Infectious Diseases 9.2. Oncology Testing 9.2.1. Breast Cancer 9.2.2. Colorectal Cancer 9.2.3. Lung Cancer 9.2.4. Prostate Cancer 9.2.5. Other Cancers 9.3. Genetic Tests 9.4. Other Applications 10. Molecular Diagnostics Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Diagnostic Laboratories 10.2. Hospitals and Clinics 10.3. Other End Users 11. North America Molecular Diagnostics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America Molecular Diagnostics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe Molecular Diagnostics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific Molecular Diagnostics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. F. Hoffmann-La Roche Ltd. 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Hologic, Inc. 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. BioMérieux SA 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Abbott Laboratories 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Qiagen 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Thermo Fisher Scientific Inc. 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Siemens Healthineers AG 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Danaher Corporation 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Myriad Genetics Inc. 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Illumina Inc. 17.10.1.Company Overview 17.10.2.Product Portfolio 17.10.3.SWOT Analysis 17.10.4.Financial Overview 17.10.5.Strategic Overview 17.11. Agilent Technologies Inc. 17.11.1.Company Overview 17.11.2.Product Portfolio 17.11.3.SWOT Analysis 17.11.4.Financial Overview 17.11.5.Strategic Overview 17.12. Becton, Dickinson and Company 17.12.1.Company Overview 17.12.2.Product Portfolio 17.12.3.SWOT Analysis 17.12.4.Financial Overview 17.12.5.Strategic Overview 17.13. DiaSorin S.p.A 17.13.1.Company Overview 17.13.2.Product Portfolio 17.13.3.SWOT Analysis 17.13.4.Financial Overview 17.13.5.Strategic Overview 17.14. Grifols S.A. 17.14.1.Company Overview 17.14.2.Product Portfolio 17.14.3.SWOT Analysis 17.14.4.Financial Overview 17.14.5.Strategic Overview 17.15. Quidel Corporation 17.15.1.Company Overview 17.15.2.Product Portfolio 17.15.3.SWOT Analysis 17.15.4.Financial Overview 17.15.5.Strategic Overview 17.16. Genetic Signatures 17.16.1.Company Overview 17.16.2.Product Portfolio 17.16.3.SWOT Analysis 17.16.4.Financial Overview 17.16.5.Strategic Overview 17.17. MDxHealth, Inc. 17.17.1.Company Overview 17.17.2.Product Portfolio 17.17.3.SWOT Analysis 17.17.4.Financial Overview 17.17.5.Strategic Overview 17.18. Exact Sciences Corporation 17.18.1.Company Overview 17.18.2.Product Portfolio 17.18.3.SWOT Analysis 17.18.4.Financial Overview 17.18.5.Strategic Overview 17.19.Biocartis NV 17.19.1.Company Overview 17.19.2.Product Portfolio 17.19.3.SWOT Analysis 17.19.4.Financial Overview 17.19.5.Strategic Overview 17.20. TBG Diagnostics Ltd. 17.20.1.Company Overview 17.20.2.Product Portfolio 17.20.3.SWOT Analysis 17.20.4.Financial Overview 17.20.5.Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study
3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Molecular Diagnostics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Molecular Diagnostics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Molecular Diagnostics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Molecular Diagnostics Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Reagents & kits 7.2. Instruments 7.2.1. Tabletop Instruments 7.2.2. Portable & PoC Instruments 7.3. Services & Software
8. Molecular Diagnostics Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Polymerase Chain Reaction (PCR) 8.2. Isothermal Nucleic Acid Amplification Technology (INAAT) 8.3. DNA Sequencing & Next-Generation Sequencing (NGS) 8.4. In Situ Hybridization (ISH) 8.5. DNA Microarrays 8.6. Other technologies
9. Molecular Diagnostics Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Infectious Disease Diagnostics 9.1.1. COVID-19 9.1.2. Hepatitis 9.1.3. HIV 9.1.4. CT/NG 9.1.5. HAI 9.1.6. HPV 9.1.7. Tuberculosis 9.1.8. Influenza 9.1.9. Other Infectious Diseases 9.2. Oncology Testing 9.2.1. Breast Cancer 9.2.2. Colorectal Cancer 9.2.3. Lung Cancer 9.2.4. Prostate Cancer 9.2.5. Other Cancers 9.3. Genetic Tests 9.4. Other Applications
10. Molecular Diagnostics Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Diagnostic Laboratories 10.2. Hospitals and Clinics 10.3. Other End Users
11. North America Molecular Diagnostics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028
12. Latin America Molecular Diagnostics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028
13. Europe Molecular Diagnostics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028
14. Asia Pacific Molecular Diagnostics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
15. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. F. Hoffmann-La Roche Ltd. 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Hologic, Inc. 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. BioMérieux SA 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Abbott Laboratories 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Qiagen 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Thermo Fisher Scientific Inc. 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Siemens Healthineers AG 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Danaher Corporation 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Myriad Genetics Inc. 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Illumina Inc. 17.10.1.Company Overview 17.10.2.Product Portfolio 17.10.3.SWOT Analysis 17.10.4.Financial Overview 17.10.5.Strategic Overview 17.11. Agilent Technologies Inc. 17.11.1.Company Overview 17.11.2.Product Portfolio 17.11.3.SWOT Analysis 17.11.4.Financial Overview 17.11.5.Strategic Overview 17.12. Becton, Dickinson and Company 17.12.1.Company Overview 17.12.2.Product Portfolio 17.12.3.SWOT Analysis 17.12.4.Financial Overview 17.12.5.Strategic Overview 17.13. DiaSorin S.p.A 17.13.1.Company Overview 17.13.2.Product Portfolio 17.13.3.SWOT Analysis 17.13.4.Financial Overview 17.13.5.Strategic Overview 17.14. Grifols S.A. 17.14.1.Company Overview 17.14.2.Product Portfolio 17.14.3.SWOT Analysis 17.14.4.Financial Overview 17.14.5.Strategic Overview 17.15. Quidel Corporation 17.15.1.Company Overview 17.15.2.Product Portfolio 17.15.3.SWOT Analysis 17.15.4.Financial Overview 17.15.5.Strategic Overview 17.16. Genetic Signatures 17.16.1.Company Overview 17.16.2.Product Portfolio 17.16.3.SWOT Analysis 17.16.4.Financial Overview 17.16.5.Strategic Overview 17.17. MDxHealth, Inc. 17.17.1.Company Overview 17.17.2.Product Portfolio 17.17.3.SWOT Analysis 17.17.4.Financial Overview 17.17.5.Strategic Overview 17.18. Exact Sciences Corporation 17.18.1.Company Overview 17.18.2.Product Portfolio 17.18.3.SWOT Analysis 17.18.4.Financial Overview 17.18.5.Strategic Overview 17.19.Biocartis NV 17.19.1.Company Overview 17.19.2.Product Portfolio 17.19.3.SWOT Analysis 17.19.4.Financial Overview 17.19.5.Strategic Overview 17.20. TBG Diagnostics Ltd. 17.20.1.Company Overview 17.20.2.Product Portfolio 17.20.3.SWOT Analysis 17.20.4.Financial Overview 17.20.5.Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics